Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 87,668 |
|
|||||
| News | - | ||||||
| Day High | 1.5945 | Low High |
|||||
| Day Low | 1.48 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Scynexis Inc | SCYX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.05 | -3.23% | 1.50 | 16:30:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.58 | 1.48 | 1.5945 | 1.50 | 1.55 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 534 | 87,668 | $ 1.52 | $ 133,637 | - | 1.35 - 3.87 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:53:11 | 10 | $ 1.56 | USD |
Scynexis Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 55.44M | 37.21M | - | 140.14M | 67.04M | 1.80 | 0.83 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Scynexis News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SCYX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.40 | 1.6058 | 1.37 | 1.46 | 112,532 | 0.10 | 7.14% |
| 1 Month | 1.41 | 1.86 | 1.37 | 1.57 | 204,498 | 0.09 | 6.38% |
| 3 Months | 1.92 | 2.17 | 1.35 | 1.64 | 206,184 | -0.42 | -21.88% |
| 6 Months | 1.77 | 2.37 | 1.35 | 1.74 | 211,864 | -0.27 | -15.25% |
| 1 Year | 3.21 | 3.87 | 1.35 | 2.39 | 304,703 | -1.71 | -53.27% |
| 3 Years | 7.44 | 11.30 | 1.15 | 3.88 | 405,039 | -5.94 | -79.84% |
| 5 Years | 1.71 | 11.30 | 0.50 | 3.16 | 469,424 | -0.21 | -12.28% |
Scynexis Description
| SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains. |
